Search clinical trials for: ADCT-301

Total 5002 results

ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
Gwynn Long, M.D.
ADC Therapeutics S.A.

Terminated

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasm (MDS/MPN)

United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States, United Kingdom
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...

United States, Belgium, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Ad Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants (HVTN139)

HIV Infections

South Africa
EGEN, Inc.

Terminated

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Colorectal Cancer

United States
University of Washington

Recruiting

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Refractory Mantle Cell Lymphoma | Recurrent Follicular... and other conditions

United States
Virion Therapeutics

Recruiting

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

Hong Kong, New Zealand
Hookipa Biotech GmbH

Recruiting

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Swiss Tropical & Public Health Institute
Pevion Biotech Ltd; Mymetics Corporation

Completed

Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)

Falciparum Malaria

Tanzania
Ospedale San Raffaele

Unknown

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) (COMBAT-19)

Covid-19 | Acute Respiratory Failure | ARDS, Human | Sars-CoV2 | Viral Pneumonia

Italy
Orion Corporation, Orion Pharma
Bayer

Completed

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects (ARIADME)

Healthy

United Kingdom
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Gastric Cancer | Advanced Solid Tumor | Pancreas Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Dyslipidemias

Korea, Republic of
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
The Catholic University of Korea

Unknown

Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo

Vitiligo

Korea, Republic of
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Woolcock Institute of Medical Research
University of Sydney

Completed

Cannabinol Use in Patients With Insomnia Disorder (CUPID)

Insomnia Disorder

Australia
European Organisation for Research and Treatment...
Bayer

Active, not recruiting

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Prostate Cancer

Belgium, Spain, France, Italy
Actelion

Completed

Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United Kingdom, Austria, Belgium, France, Germany, Hungary, Italy, Poland
Sensei Biotherapeutics, Inc.
Accelovance

Completed

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Prostate Cancer

United States
Medtronic Cardiovascular

Completed

Medtronic HAMMOCK Post Approval Study

Heart Valve Diseases

United States, Germany, Poland
National Cancer Institute (NCI)

Recruiting

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, Adrenocortical

United States
Kiora Pharmaceuticals, Inc.

Recruiting

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (ABACUS)

Retinitis Pigmentosa | Choroideremia

Australia
LYSOGENE

Completed

Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy

Mucopolysaccharidosis Type III A | Sanfilippo Disease Type A

France
LYSOGENE

Completed

Intracerebral Gene Therapy for Sanfilippo Type A Syndrome

Mucopolysaccharidosis Type III A | Sanfilippo Disease Type A

France
Lumen Bioscience, Inc.

Recruiting

A Study to Determine the Tolerability of Intranasal LMN-301

COVID-19

Australia
University of Alabama at Birmingham

Recruiting

NTX-301 in MDS/AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Kodiak Sciences Inc

Terminated

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age-related Macular Degeneration

United States
Oncolys BioPharma Inc
Medigen Biotechnology Corporation

Unknown

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Taiwan, Korea, Republic of
Sensei Biotherapeutics, Inc.

Withdrawn

SNS-301 Monotherapy in High Risk MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia (CMML)
Celldex Therapeutics

Completed

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Healthy

United States
Neuramedy Co. Ltd.
Quotient Sciences

Not yet recruiting

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

Parkinson Disease

United Kingdom
Benitec Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Oculopharyngeal Muscular Dystrophy

United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
National Institute of Diabetes and Digestive and...

Not yet recruiting

Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and Immunoregulation

Obesity | Body Weight

United States
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Chronic Migraine or Episodic Migraine

United States, Germany, Austria, Czechia, Canada, Denmark, Finland, Sweden
Syneos Health
Oncolys BioPharma Inc

Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Melanoma Stage Iv | Melanoma Stage III

United States
Oncolys BioPharma Inc

Unknown

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan

Search clinical trials for: ADCT-301

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations